Citigroup Downgrades Sabra Health Care REIT to Hold with $19 Target
Citigroup analyst Nick Joseph lowered Sabra Health Care REIT's rating to hold, setting a $19 price target, a 1.61% downside from the current price.
Key Points
- Citigroup downgraded Sabra Health Care REIT to a hold rating on June 23, 2026, with a price target of $19.
- Citigroup's $19 price target implies 1.61% downside from Sabra Health Care REIT, Inc.'s ($SBRA) current $19.31 share price.
- Shares of Sabra Health Care REIT traded near $18.27 on Tuesday, with a market cap of about $4.61 billion.
- Recent insider buying involved multiple executives purchasing 8,310 shares each on June 17, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citigroup analyst Nick Joseph downgraded Sabra Health Care REIT, Inc. (NasdaqGS:SBRA) to a hold rating on June 23, 2026, with a price target set at $19. This move reflects a cautious stance on the healthcare-focused real estate investment trust.
Citigroup vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Sabra Health Care REIT
BlackRock, Inc. increased its holdings in Sabra by 704,770 shares, bringing its total to 39,098,389 shares valued at approximately $751.9 million, marking a 1.8% increase. Principal Financial Group Inc. added 98,770 shares, ending with 25,052,121 shares worth about $481.8 million, a 0.4% rise. Vanguard Portfolio Management LLC opened a new position with 23,143,248 shares valued at $445 million. State Street Corp grew its stake by 198,311 shares to 12,099,951 shares, valued at $232.7 million, a 1.7% increase. Meanwhile, JPMorgan Chase & Co boosted its position by 5,569,621 shares, resulting in 8,201,220 shares valued at $159.4 million, a 211.6% increase.
Sabra Health Care REIT, Inc. Stock Down 6.3%
Shares of Sabra Health Care REIT traded near $18.27 on Tuesday. The company has a market cap of approximately $4.61 billion and a P/E ratio of 29.0. Its forward P/E is 24.58, and it has a beta of 0.626. Sabra's 52-week range is between $17.17 and $21.28, with a 50-day moving average of $19.94 and a 200-day moving average of $19.31. The company maintains a current ratio of 2.623 and a quick ratio of 1.99, with a debt-to-equity ratio of 95.86.
$SBRA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Sabra Health Care REIT reported revenue of $815.7 million, with a growth rate of 21.7%. The net margin stands at 19.1%, while return on equity is 5.68%. The company posted earnings per share of $0.63. Sabra is scheduled to announce its next earnings on August 3, 2026.
Dividend
Sabra Health Care REIT offers an annual dividend rate of $1.20, yielding 6.62%. The dividend payout ratio is high at 190.48%, indicating the company returns a significant portion of its earnings to shareholders.
Insider Buying and Selling at Sabra Health Care REIT, Inc.
On June 17, 2026, several insiders, including Ann Kono, Lynne Katzmann, Catherine Cusack, Michael Foster, Jeffrey Malehorn, and Craig Barbarosh, each purchased 8,310 shares. These transactions did not occur under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 23, 2026, Citigroup downgraded Sabra Health Care REIT to a hold rating, setting a price target of $19. Scotiabank maintained its hold rating with the same target on June 18, 2026. Wells Fargo, on June 1, 2026, maintained a buy rating with a $23 target. The consensus recommendation is a buy with an average target price of $22.54 based on 13 analyst opinions.
About Sabra Health Care REIT
Sabra Health Care REIT, Inc. is a real estate investment trust focused on owning and investing in properties serving the healthcare industry across the United States and Canada. Headquartered in Tustin, California, and led by CEO Richard K. Matros, the company was established in 2010 and operates with a small team of 58 employees.
Bottom Line
Citigroup's downgrade of Sabra Health Care REIT to a hold rating reflects a cautious outlook on the stock. Investors often track such analyst ratings for insights into market sentiment. It's important to note that these ratings are backward-looking and might not represent current market conditions. As always, investors should consider multiple sources and factors when evaluating a stock.
Get Sabra Health Care REIT, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SBRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.